Clear ×
Aquestive Therapeutics, Inc. AQST

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Oct 19, 2026 8-K 4 signals fired
Other
Director Officer Indemnification Provision Stock Certificate Signature Requirement Equity Plan Board Approval Conditional On Shareholder Vote President Duties Defined
Oct 15, 2026 8-K 5 signals fired
Other
Priority Review Or Pdufa Disclosed Safety Differentiated
Core
Indication Expansion Near Term Regulatory Decision
Biotech Risk
Crl Received
Oct 14, 2026 8-K 11 signals fired
Core
Regulatory Designation Only Indication Expansion Near Term Regulatory Decision
Other
Fast Track Designation Received Patent Family Portfolio Disclosure Fast Track Granted Orphan Status Granted Breakthrough Therapy Granted Priority Review Or Pdufa Disclosed Rmat Designation Received
Biotech Risk
Orphan Drug Designation
Sep 29, 2026 8-K 3 signals fired
Other
Classified Board Director Election Board Diversity Policy Disclosed Executive Transition Gratitude Statement
Sep 25, 2026 8-K 5 signals fired
Biotech Risk
Crl Received
Core
Clinical Trial Result
Other
Safety Differentiated Patient Retention High Interim Data Positive
Sep 17, 2026 8-K 9 signals fired
Other
Ceo Team Pride Statement Interim Data Positive Board Committee Member Listing
Core
Clinical Trial Result Indication Expansion Secondary Endpoint Mentioned
Biotech Risk
Crl Received Trial Endpoint Missed Accelerated Approval
Aug 11, 2026 10-Q 60 signals fired · top 15
Other
Tenant Restoration Obligation Operating Lease Rent Expense Disclosed Liquidity Position Snapshot Disclosed Warrant Valued Black Scholes Use Of Proceeds Disclosure Cash Flow Statement Investing Activities Corporate Authority Representation Rsu Psu Vesting Schedule Disclosed Stock Option Grant Disclosed Debt Note Interest Terms Disclosed Amendment Modification Waiver Clause Credit Agreement Schedule Amendment Effective Tax Rate Reconciliation Libor Based Term Loan Pricing
Business Services
Demand Softening
Aug 11, 2026 8-K 13 signals fired
Core
Secondary Endpoint Mentioned Indication Expansion Clinical Trial Result Regulatory Designation Only
Other
Earnings Call Replay Details Net Loss Reported Interim Data Positive Adjusted Ebitda Period Comparison Liquidity Position Snapshot Disclosed Fda Aligned Safety Differentiated
Healthcare
Pricing Power Services
Biotech Risk
Crl Received
Aug 10, 2026 8-K 9 signals fired
Biotech Risk
Crl Received
Core
Clinical Trial Result Indication Expansion
Other
Kol Endorsement Patient Retention High Interim Data Positive Fda Aligned Publication Positive
Healthcare
Reimbursement Improving
Jun 10, 2026 8-K 2 signals fired
Other
Auditor Appointment Ratification Classified Board Director Election
May 13, 2026 10-Q 49 signals fired · top 15
Other
Warrant Valued Black Scholes Liquidity Position Snapshot Disclosed Operating Lease Rent Expense Disclosed Rsu Psu Vesting Schedule Disclosed Director Officer Indemnification Provision Effective Tax Rate Reconciliation Employment Termination Upon Death Cash Flow Statement Investing Activities Stock Option Grant Disclosed Depreciation Expense Composition Disclosure Revenue Decline Explanation Confidential Information Return Obligation Priority Review Or Pdufa Disclosed Financing Activities Cash Flow Disclosure
Core
Clinical Trial Result
May 13, 2026 8-K 22 signals fired · top 15
Other
Use Of Proceeds Disclosure Libor Based Term Loan Pricing Liquidity Position Snapshot Disclosed Headcount Disclosure Standard Net Loss Reported Personnel Cost Decrease Disclosure Adjusted Ebitda Period Comparison Patient Retention High Ceo Earnings Call Commentary Interim Data Positive Administrative Efficiency
Core
Clinical Trial Result Lead Asset Progress
Healthcare
Pricing Power Services
Biotech Risk
Crl Received